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Abstract  26 
High expression of vascular endothelial growth factor C (VEGFC) predicts adverse prognosis 27 
in acute myeloid leukemia (AML). We therefore explored VEGFC targeting efficacy as an 28 
AML therapy using a VEGFC monoclonal antibody. VEGFC antibody therapy enforced 29 
myelocytic differentiation of clonal CD34+ AML blasts. Treatment of CD34+ AML blasts with 30 
the antibody reduced expansion potential by 30-50% and enhanced differentiation via 31 
FOXO3A suppression and inhibition of MAPK/ERK proliferative signals. VEGFC antibody 32 
therapy also accelerated leukemia cell differentiation in a systemic humanized AML mouse 33 
model. Collectively, these results define a regulatory function of VEGFC in CD34+ AML cell 34 
fate decisions via FOXO3A and serve as a new potential differentiation therapy for AML 35 
patients. 36 
 37 
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Significance 40 
Findings reveal VEGFC targeting as a promising new differentiation therapy in AML.  41 
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Introduction 42 
Vascular Endothelial Growth Factor C (VEGFC) is one of the VEGF family members with a 43 
unique role in lymphangiogenesis as well as in angiogenesis in normal homeostasis and 44 
cancer.(1-4) VEGFC can bind to kinase insert domain receptor (KDR, i.e. VEGFR-2) and 45 
fms-related tyrosine kinase-4 (FLT-4, i.e. VEGFR-3) receptors expressed by vascular 46 
endothelial cells, lymphatic endothelial cells, and by leukemic blasts.(1-3, 5, 6) KDR is 47 
expressed extracellular on the acute myeloid leukemia (AML) cell membrane, intracellular in 48 
the cytoplasm and on the nuclear membrane of AML cells, while FLT-4 mainly stains positive 49 
within the cytoplasm of AML blasts.(5-7) This phenomenon implicates that the extrinsic 50 
VEGFC/KDR axis is more likely to support AML cells due to the limited availability of FLT-4 in 51 
these AML cells. 52 
High VEGFC levels were identified as an independent prognostic factor in AML and 53 
associated with decreased complete remission rates and a reduced survival.(8) Exogenous 54 
VEGFC can protect AML cells from chemotherapy induced apoptosis.(5) We previously 55 
showed that endogenous VEGFC expression is associated with decreased drug 56 
responsiveness in childhood AML.(9) We therefore hypothesized that VEGFC is an important 57 
autocrine growth factor involved in CD34+ AML blast maintenance.  58 
Current literature supports an important function for VEGFC in AML progression and therapy 59 
resistance.(5, 8, 9) Nevertheless, the downstream mechanism of VEGFC signaling in AML 60 
blasts is still unknown, and its potential as therapeutic target in AML is an unexplored field of 61 
research. Therefore, we set out to investigate the contribution of VEGFC on AML cell 62 
functions and the associated downstream signal transduction regulation. 63 
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Methods 65 
AML patient samples Medical Ethical Committee approved METC 2010.036 and 2013.281, 66 
UMCG the Netherlands. After obtained written informed consent (according the declaration 67 
of Helsinki), patient samples were handled as was previously described.(7) Table S1 68 
includes AML patient characteristics as FAB, karyotype, blast (%), VEGFC levels (pg/mL), 69 
KDR (%), FLT-4 (%), CD34 (%), and FLT3 mutational status. 70 
Cell lines THP-1 and OCI AML3 AML cells were obtained from the American Type Culture 71 
Collection (ATCC and DSMZ), cultured in RPMI-1640 medium (Thermo Fisher) 72 
supplemented with 1% penicillin/ streptomycin (Thermo Fisher) and 10% fetal calf serum 73 
(FCS, Bodinco). MS5 bone marrow stromal feeder layer (a kind gift from J.J. Schuringa from 74 
the Dept. Experimental Hematology, University Medical Center Groningen). Cell lines were 75 
all tested mycoplasma free and ~25 times passaged. Cell line karyotypes were regularly 76 
tested and were maintained among passages. 77 
Cloning lentiviral vectors shRNA sequences targeting VEGFC, VEGFR-2/KDR (Supp. 78 
Table S2) were genetically modified into a pLKO1-mCherry vector and PCR amplified 79 
FOXO3A was cloned into the pRRL-GFP vector. Lentiviral particles were generated by 293T 80 
cells using psPAX2, pMD2.G (VSV-G) and FuGENE (Roche). 81 
Flow cytometry Cells were serum blocked, stained with primary antibodies and secondary 82 
antibodies (Table S2). Intracellular stainings were performed according to manufacturer’s 83 
protocol (Fix & Perm, Life Technologies). Annexin V-FITC(/PI) staining for apoptosis 84 
following manufacturer’s protocol (Annexin-V-FLUOS staining kit, Roche). Samples were 85 
analyzed using LSRII (BD FACS DIVA software, BD bioscience) and FlowJo software (Tree 86 
Star Inc.).  87 
VEGFC enzyme-Linked ImmunoSorbent Assay (ELISA) The VEGFC protein expression 88 
in patient samples was measured in duplicates using a VEGFC ELISA (R&D Systems) 89 
following manufacturers protocol. 90 
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Compounds VGX-100 is a human monoclonal VEGFC antibody (a kind gift from Vegenics 91 
Pty Ltd). VGX-100 binds to and precipitates all forms of VEGF-C in both the human and 92 
mouse. 93 
CD34+ short-term and long-term culture assays CD34+ cells were isolated using a 94 
MoFlo-XDP sorter (Beckman Coulter). After CD34 sorting, the CD34 percentages exceeded 95 
95% in all samples. Human short-term Colony-Forming Cell (CFC) assay. A total of 1000 96 
CD34+ sorted MNCs were cultured for 2 weeks in 1 mL methylcellulose (MethoCult® H4435 97 
Enriched, Stem cell technologies) according to manufacturer’s protocol, experiment is 98 
performed in duplicate per patient sample. Long-term culture-initiating cell (LTC-IC) 99 
assay. CD34+ sorted blasts are cultured on MS5 mouse bone marrow stromal cells, in 100 
Gartner’s media; αMEM (Thermo Fisher) containing 12.5% FCS, 12.5% horse serum 101 
(Thermo Fisher), 1% penicillin/streptomycin, 57.2 µM β-mercaptoethanol (Sigma-Aldrich), 102 
and 1 µM hydrocortisone (Sigma-Aldrich), supplemented with 20 ng/mL trombopoietin (TPO, 103 
a kind gift from Kirin Brewery), IL-3 (Gibco), and granulocyte colony-stimulating factor (G-104 
CSF, Invitrogen), experiment is performed in duplicate per patient sample. LTC-IC assay in 105 
limiting dilution. LTC-IC assay plated at a density range 106 
(1/5/10/50/100/250/40.000/120.000 cells/well) were subjected to CFC methylcellulose on top 107 
of the stroma (MS5) at week 5 of co-culturing. Experiment is performed in 10-plo per density 108 
per patient sample. 109 
Microscopy Cytospins were stained with May-Grunwald-Giemsa (MGG). Images were taken 110 
with a Leica DM 3000 or Leica DM IL microscope with a Leica DFC420C camera (Leica 111 
Geosystems B.V.). Histological analysis of the sternum (bone marrow) and spleens of AML 112 
xenografted mice was outsourced to the Histology Core Facility of VIB, Leuven. 113 
Western Blot (WB) Cells were lysed in Laemmli sample buffer (Bio-rad). Proteins were 114 
separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred to 115 
nitrocellulose membranes, and incubated overnight with primary antibodies (Table S2), 116 
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washed, and incubated with HRP conjugated secondary antibodies. Protein bands were 117 
visualized by chemiluminescence. Phospho-proteome array (R&D systems) analysis was 118 
performed according to manufacturer’s protocol and data analysis and normalisation was 119 
performed as previously described.(7) 120 
FLT3-ITD fragment analysis Fluorescent labeling technology and fragment length analysis 121 
to establish the ratio of the mutant (ITD) FLT3 allele to the wild type (WT) FLT3 allele. Ratios 122 
up to 0.5 are indicative for a heterozygous FLT3-ITD mutant allele present in 100% of the 123 
AML cells (1 ITD peak/ (1 ITD peak + 1 WT peak) = 0.5). Newly diagnosed patients with AML 124 
harbor a heterozygous FLT3-ITD mutation in >92% of the cases.(10) 125 
Reversed Phase Protein Array (RPPA) Proteomic profiling was performed using newly 126 
diagnosed pediatric AML samples (n=31) and CD34+ NBM samples (n=10) using RPPA, as 127 
described previously.(11) 128 
Quantitative Real-Time polymerase chain reaction (qRT-PCR) FOXO3A, CD11b, and 129 
p21 mRNA expression together with HPRT as a reference gene were analyzed in triplicates 130 
using SYBR Green qRT-PCR (Bio-rad laboratories, Veenendaal, The Netherlands). Relative 131 
mRNA expression from triplicates was determined using the ΔΔCt method (primer 132 
sequences Table S2). 133 
AML xenografted in NOD-SCID/IL2γ-/- (NSG) mice NSG mice were purchased from 134 
Charles River. This animal study was approved by the ethical animal committee at KU 135 
Leuven (P262/2015). Animals received anti-VEGFC 40 mg/kg treatment twice a week via i.p. 136 
injections. Animals were injected with 106 primary AML cells i.v. White blood cell counts were 137 
measured using a micro-semi CRP hematology analyzer (Axonlab). 138 
Statistics Statistical package for the social science (SPSS 17) software was used for 139 
graphing box-plots. Mann-Whitney U test was used to determine differences between AML 140 
and NBM or two experimental groups of mice, two-tailed Student’s t-tests or a paired sample 141 
t-test were used for analysis comparing untreated and treated AML cells based upon 142 
Research. 
on September 10, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 5, 2018; DOI: 10.1158/0008-5472.CAN-18-0250 
VEGFC antibody therapy drives differentiation of AML 
 8 
Levene’s test for equality of variance, Kruskal-Wallis test was used to define significant 143 
differences between more than two groups. 144 
145 
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Results 146 
The VEGFC/KDR axis is selectively expressed by AML blasts 147 
VEGFC is an important prognostic factor in AML supporting AML blast growth and apoptosis 148 
evading signals (Figure S1A/B/C). The CD34+ and CD34- cell populations within primary 149 
AML patients samples expressed significantly higher levels of VEGFC as compared to NBM 150 
controls (Figure 1A, Kruskall-Wallis test, P = 0.013). Associated to higher VEGFC 151 
expression, primary AML patient samples present elevated KDR membrane protein 152 
expression levels (Figure 1A, Mann-Whitney U test, P = 0.001), while FLT-4 membrane 153 
protein expression was absent (Fig 1A, Mann-Whitney U test, P = 0.381).(7) In support of 154 
these data, VEGFC and KDR knockdown effects on the proliferation of AML cell lines was 155 
comparable (Figure S2A). Cell cycle inhibitor p21 mRNA expression was significantly 156 
induced in anti-VEGFC treated as well as VEGFC knockdown AML cells (Figure S2B). 157 
Additionally, VEGFC supporting effects on AML cell growth were suppressed in KDR 158 
knockdown cells (Figure S2C). These findings, challenged us to explorer VEGFC (30 µg/mL) 159 
monoclonal antibody treatment effects on AML cell functions (Figure 1B). 160 
 161 
VEGFC antibody therapy eliminates the expansion potential of CD34+ AML cells by 162 
enforcing myelocytic differentiation 163 
In KDR expressing AML cell line THP-1, VEGFC antibody therapy significantly induced 164 
myelocytic differentiation, supported by an increased population of cells that express 165 
differentiation markers CD11b and CD14 (Figure 1C/D and S3A, Student’s t-test, both P < 166 
0.05). Additionally, VEGFC antibody therapy induced apoptosis in a dose-dependent matter 167 
(Figure 1E). VEGFC antibody therapy reduced KDR membrane expression, which implicates 168 
an eradication of the VEGFC/KDR axis in these leukemic cells (Figure 1F).  169 
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Next, VEGFC antibody therapy effects on CD34+ primary AML samples (Figure S3B/C) was 170 
examined in a variety of AML stem/progenitor cell assays. Colony forming cell assays (CFC 171 
assay, 3D semi-solid media) highlight a 25% reduction in four AML patient samples and one 172 
AML patient sample showed decreased colony formation solely after serial re-plate (Figure 173 
2A, combining all performed CD34+ AML patient CFC assays, Mann-Whitney U test, P = 174 
0.0192). VEGFC antibody therapy suppressive colony formation was supported by 35% 175 
lower total CFC cell counts in all AML samples (Figure 2A, Mann-Whitney U test, P = 176 
0.0028). In long-term culture initiating cells assays (LTC-IC, 3D co-culture assay), VEGFC 177 
antibody therapy decreased the outgrowth of CD34+ AML cells in 6 out of the 7 AML patient 178 
samples, overall reducing the LTC-IC outgrowth by 28% (Figure 2B, Mann-Whitney U test, P 179 
= 0.003).  Although LTC-IC assays outgrowth was reduced by VEGFC antibody therapy, 180 
LTC-IC cultures were retained in the presence of VEGFC antibody therapy. Limiting dilution 181 
LTC-IC assays revealed a further decrease up to 49% in the CD34+ initiating leukemic cell 182 
outgrowth potential in the presence of anti-VEGFC (Figure 2C/D, Mann-Whitney U test, P = 183 
0.003). Morphological analysis revealed VEGFC antibody therapy induced myelocytic 184 
differentiation that appeared already after one week of treatment (Figure 2E/F).  185 
Besides an overall 28% reduction in the outgrowth of VEGFC antibody treated CD34+ AML 186 
blasts, a significant 3.3-fold induction of differentiation along the myelocytic lineage could be 187 
appreciated in LTC-IC assays (Figure 2G, Mann-Whitney U test, P = 0.001). Differentiation 188 
marker analysis confirmed that increasing percentages of cells stained positive for CD38, 189 
CD11b and CD14 or CD15 cells in liquid cultures, CFC assays and LTC-IC assays as 190 
compared to untreated controls (Figure 2H and S3D/E), while CD34 percentages were 191 
decreased. In addition, VEGFC antibody treated cultures presented increased percentages 192 
of apoptotic cells (Figure 2I and S3D).  193 
 194 
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VEGFC antibody therapy targeted myelomonocytic differentiation of the leukemic 195 
clone 196 
FLT3-ITD fragment analysis showed identical ratios of heterozygous FLT3-ITD mutant cells 197 
in untreated and VEGFC antibody treated cultures in CFC and LTC-IC assays (Table S3), 198 
supporting that anti-VEGFC treatment affects the leukemic clone. While the FLT3-ITD 199 
leukemic cells were affected by VEGFC antibody enforced myelomonocytic differentiation, 200 
the cellular responses for FLT3-WT AML samples were superior to the FLT3-ITD AML 201 
samples (Figure S4A, Mann-Whitney U test, P = 0.042). VEGFC antibody therapy of control 202 
CD34+ NBM cultures presented an approximate 3-4 weeks latency in myelocytic lineage 203 
skewing as compared to AML CD34+ cells (Figure S4B/C). Overall, these findings highlight 204 
that VEGFC antibody treatment is a novel new differentiation therapy, which targets the 205 
leukemic clonogenic capacity of CD34+ AML blasts. 206 
 207 
VEGFC antibody therapy targeted downstream MEK1/2/Erk1/2 phosphorylation in AML 208 
blasts 209 
As a first approach to define VEGFC downstream targets, we analyzed phospho-proteome 210 
arrays of three independent untreated and VEGFC antibody treated AML samples. 211 
Phosphorylation of MEK1/2 (S218/S222, S222/S226), AMPKα2 (T172), HSP27 (S78/S82), 212 
Paxillin (Y118), STAT2 (Y689), and STAT5b (Y699) were significantly reduced in anti-VEGFC 213 
treated AML samples (Figure 3A, paired samples t-test, mean ± SEM, * P < 0.05). 214 
Decreased phosphorylation of specifically ERK1/2 was confirmed by immunoblot analysis, 215 
and STAT5a/b was reduced in some cases in anti-VEGFC treated CD34+ AML samples, and 216 
not in CD34+ NBM (Figure 3B, Mann-Whitney U test, P = 0.008 for Erk, and P = 0,151 for 217 
STAT5). In the previously performed LTC-IC assays in limiting dilutions, we observed a loss 218 
of erythropoiesis in some but not all AML patient samples, which is supported by reduced 219 
STAT5 phosphorylation. While reduced levels of Erk1/2 phosphorylation can explain a 220 
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potential drop in expansion potential of the AML blasts by VEGFC antibody therapy, these 221 
findings cannot explain the induction of myelomonocytic differentiation.(7) 222 
 223 
VEGFC antibody therapy induced myelomonocytic differentiation via FOXO3A 224 
suppression 225 
Next, we combined flow cytometry VEGFC and KDR protein expression analysis together 226 
with reverse phase protein array (RPPA) analysis of the same set of pediatric AML samples. 227 
The VEGFC/KDR protein association network showed strong significant overlapping 228 
correlations for CCND3, LGALS3, FOXO3 (S318/321), PRKCD (S645), KIT, LSD1, NPM1, 229 
EIF2AK2, PTPN11, SSBP2, STAT5A/B (Figure 3C, Pearson correlations, all P < 0.05). 230 
FOXO3 suppression is described to mediate differentiation of the AML blasts.(12) In line with 231 
previous reports in adult AML samples, the basal and phosphorylated FOXO3A protein 232 
expression levels were significantly increased in pediatric AML as compared to CD34+ NBM 233 
samples (Figure S4D, Student’s t-test, both P < 0.001).(13) Immunoblot and flow cytometry 234 
analysis, revealed that FOXO3A protein expression was decreased upon VEGFC antibody 235 
treatment in THP-1 cells and primary AML samples (Figure 3D). To define whether VEGFC 236 
antibody therapy induced myelomonocytic differentiation was facilitated via its suppression of 237 
FOXO3A, we generated THP-1 FOXO3A overexpression cells. Constitutive FOXO3A 238 
overexpression was shown to rescue the anti-VEGFC induced expression of CD11b in a 239 
dose-dependent manner (Figure 3E and S4E/F, Student’s t-test, 30 μg/mL P = 0.027 and 60 240 
μg/mL P = 0.019). These findings implicate that anti-VEGFC induced differentiation of 241 
leukemic cells was enforced via the suppression of FOXO3A. 242 
 243 
VEGFC antibody therapy reduced splenic AML infiltration and induced 244 
myelomonocytic differentiation in an AML xenograft animal model 245 
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To investigate the in vivo VEGFC targeting efficacy, we injected a primary AML patient 246 
sample (EVI1 ASXL1) into NSG mice that progressively developed leukemia’s. These 247 
patient-derived AML xenografted mice were treated with DMSO or VEGFC antibody therapy. 248 
Leukemia was presented by increased white blood cell (WBC) counts in the peripheral blood 249 
of these animals. The WBC counts were significantly reduced by VEGFC antibody therapy 250 
(Figure 4A, Mann-Whitney U test, P = 0.014). Upon disease progression, histological bone 251 
marrow examination showed that the human AML blast population was only slightly reduced 252 
in VEGFC antibody treated animals (Figure 4B/S5, Mann-Whitney U test, P = 0.127). In the 253 
bone marrow, we observed a significant induction of eosiniphilic compartment in VEGFC 254 
antibody treated mice, supported by elevated levels of human CD11b expression (Figure 255 
4B/C, Mann-Whitney U test, histology P = 0.046 and flow cytometry P = 0.007). The spleens 256 
of VEGFC antibody treated human PDX AML mice showed a minor decrease in size (Figure 257 
4D). When focusing on spleen infiltration of human xenografted AML cells, histological 258 
examinations revealed a significant reduction in the amount of AML blasts that localized to 259 
the spleens in VEGFC antibody treated mice (Figure 4D/S5, Mann-Whitney U test, P = 260 
0.011). The overall in vivo efficacy of VEGFC antibody treatment was characterized by a 261 
modest reduction in human PDX AML blast homing to the bone marrow of NSG mice, 262 
leading to a stronger decrease in human PDX AML engraftment to secondary AML sites as 263 
the spleen, where we observed a ~50% reduction of human AML blasts. Taken together, this 264 
in vivo study shows that VEGFC antibody therapy suppresses the AML progression in vivo 265 
via the induction of differentiation. 266 
267 
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Discussion 268 
VEGFC has been shown to be an independent prognostic factor and showed to interfere with 269 
AML survival in vivo and ex vivo.(5, 8, 9) Our study highlights VEGFC targeted treatment as 270 
potential new differentiation therapy in AML. This study is one of the few that showed potent 271 
differentiation of the CD34+ leukemic clone by VEGFC targeting antibody therapy in vitro and 272 
in vivo. The modest VEGFC antibody therapy mediated reduction of AML blasts in the bone 273 
marrow of NSG mice in vivo underscores the supportive therapeutic potential of VEGFC 274 
targeting differentiation therapy in addition to conventional treatment regimens for AML 275 
patients. ATRA is a differentiation therapy available as conventional therapy in the clinic, 276 
applied to all acute promyelocytic leukemia (APL) patients that harbor the PML-RARA fusion 277 
protein. This differentiation therapy significantly improved the outcome of APL.(14, 15) More 278 
recently, the IDH2 inhibitor Enasidenib was approved in the clinics as new differentiation 279 
therapy of IDH2 mutant AMLs.(16)  280 
VEGFC targeting antibody therapy is currently under investigation in a phase I clinical trial in 281 
combination with Bevacizumab (VEGFA targeting antibody) for advanced solid tumors using 282 
a maximum dosage of 20 mg/kg, which showed to be well tolerated (NCT01514123) and 283 
final results should be available soon. VEGFC targeting antibody therapy in mice was 284 
previously shown using daily dosages 20 mg/kg, which was well tolerated.(17, 18) In our 285 
study, VEGFC targeting antibody therapy at 40mg/kg twice weekly in NSG mice did not 286 
affect the animal body weight nor showed aberrant histology of organs, and was therefore 287 
well tolerated. 288 
Notably, we found that VEGFC antibody treatment blocked the erythroid outgrowth of 2 out of 289 
5 patient samples in long-term CD34+ AML cultures, which can be caused by the inhibition of 290 
STAT5 phosphorylation that is known to guide erythropoiesis.(19, 20) Evidence of similar 291 
effects should be paid attention to in the ongoing clinical trial of this compound. The VEGFC 292 
targeting therapeutic approach might be useful for other cancer subtypes as well, as for 293 
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example high VEGFC expression levels have been shown to modulate the breast cancer 294 
metastasizing capacity.(4) 295 
Our study describes that VEGFC mediated FOXO3A levels are important for the preservation 296 
of immature AML blasts. Interactions between AMPKα2 and FOXO3A have previously been 297 
described.(21) We speculate that the decreased levels of AMPKα2 protein phosphorylation 298 
by VEGFC antibody treatment may be the key substrate for FOXO3A to control AML cell 299 
fate. So far, our findings indicate an important regulatory function for VEGFC in CD34+ AML 300 
cell fate decisions. Anti-VEGFC therapy enforced CD34+ AML blast myelocytic differentiation 301 
by FOXO3A suppression, creating new opportunities for differentiation therapy besides high 302 
dose chemotherapy in AML. 303 
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Figure legends 397 
Figure 1. VEGFC targeted therapy in AML. 398 
(A) VEGFC protein expression analysis using enzyme-linked immunosorbent assay on 399 
normal bone marrow (NBM, n=4) cells, CD34- AML cells (n=3) and CD34+ AML cells (n=5). 400 
Flow cytometry KDR (VEGFR-2) membrane protein expression levels of pediatric AML blasts 401 
(n=60) and NBM (n=5) controls. FLT4 (VEGFR-3) membrane protein expression levels on 402 
pediatric AML blasts (n=18) and NBM (n=5) controls. Box-plots show the median and error 403 
bars define data distribution. (B) VEGFC targeting study approach to identify the molecular 404 
mechanism of action. (C) May-Grunwald-Giemsa (MGG) staining of THP-1 cells in the 405 
presence or absence of VEGFC targeting human antibody (30 µg/mL). (D) CD11b and CD14 406 
membrane protein expression by flow cytometric analysis of THP-1 untreated and anti-407 
VEGFC treated cells (mean ± SEM). (E) Flow cytometric dose-dependent apoptosis analysis 408 
of anti-VEGFC treated THP-1 cells using annexin V staining (mean ± SEM). (F) Flow 409 
cytometric KDR membrane protein expression analysis upon VEGFC targeting antibody 410 
treatment in THP-1 cells (mean ± SEM). Statistical analysis * p-value < 0.05. 411 
 412 
Figure 2. VEGFC targeting therapy effects on CD34+ AML stem and progenitor cells. 413 
(A) Colony forming cell (CFC) assay analysis of CD34+ pediatric AML cells using a single 414 
dose of VEGFC antibody treatment representing the number CFC colonies on the left and 415 
the total CFC cell counts on the right (n=6). (B) CD34+ AML expansion potential in long-term 416 
colony forming cell assay (LTC-IC) after 7 weeks of AML culturing on a mouse stromal 417 
feeder layer (n=7). (C) CD34+ AML expansion potential of cobblestone forming cells residing 418 
underneath the stromal layer after 5 weeks of culturing, measured in limiting dilutions by their 419 
CFC output potential (n=5). (D) CFC, LTC-IC and LTC-IC in limiting dilution represented per 420 
AML patient sample. (E) Representative MGG stained cytospins of untreated VEGFC 421 
antibody treated CD34+ AML samples in CFC and LTC-IC assays. (F) Microscopic 422 
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quantification of AML cell culture composition after LTC-IC assays analysis comparing 423 
untreated and anti-VEGFC treated cultures (n=7). (G) Box-plot presenting the mean 424 
percentage of myelomonocytic cells quantified from MGG stained cytospins comparing 425 
untreated and anti-VEGFC treated cultures. (H) Flow cytometry confirmation of anti-VEGFC 426 
induced myelomonocytic differentiation in CD34+ AML CFC and LTC-IC assays by CD38, 427 
CD34, CD11b and CD14 membrane protein expression analysis. (I) Flow cytometric annexin 428 
V/PI apoptosis analysis of untreated and anti-VEGFC treated CD34+ AML CFC and LTC-IC 429 
cultures. All box-plots represent the median and error bars define data distribution. Statistical 430 
analysis * p-value < 0.05. 431 
 432 
Figure 3. Identification of anti-VEGFC targeting mechanisms in pediatric AML and 433 
potential bypass mechanism. 434 
(A) Phospho-protein array analysis presented as VEGFC antibody targeting effects relative 435 
to untreated control CD34+ AML samples (n=3) (mean ± SEM). (B) Immunoblot confirmation 436 
of anti-VEGFC treatment effects on MAPK/Erk, and STAT5 protein expression and 437 
phosphorylation in pediatric CD34+ AML samples, CD34+ NBM controls and THP-1 cells. 438 
Left: immunoblots. Right: combined quantification of the presented immunoblots. Box-plots 439 
show the median and error bars define data distribution. (C) Flow cytometry VEGFC and 440 
KDR protein expression analysis combined with RPPA array analysis in CD34+ pediatric 441 
AML samples. The Venn diagram shows significantly overlapping protein expression. Bold 442 
proteins show a positive correlation and non-bold proteins presented a negative correlation. 443 
All shown proteins were analyzed by RPPA analysis except the ones that are described to be 444 
analyzed by flow cytometry. (D) FOXO3A immunoblot analysis of THP-1 cells treated for 72h 445 
with anti-VEGFC. Intracellular protein expression as measured by flow cytometry analysis of 446 
24h anti-VEGFC treated primary AML samples and THP-1 cells. (E) Scrambled control 447 
vector and FOXO3A constitutive overexpressing THP-1 cells in the presence or absence of 448 
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VEGFC antibody treatment, analyzed for CD11b membrane protein expression levels 449 
measured using flow cytometry analysis (mean ± SEM). Statistical analysis * p-value < 0.05. 450 
 451 
Figure 4. VEGFC antibody therapy induced differentiation in a primary AML 452 
xenografted animal model. 453 
(A) The white blood cell (WBC) counts in the peripheral blood of mice injected with a primary 454 
EVI1 ASXL1 AML sample comparing DMSO with VEGFC antibody treated animals. (B/D) 455 
Histological analyses was performed on bone marrow and spleens of disease progressed 456 
animals using a semi-quantitative scoring system e.g. 0 = no infiltration, 1 < 25% infiltration, 457 
2 = 25-75% infiltration, 3 > 75% infiltration. DMSO treated animals were compared to VEGFC 458 
antibody treated animals. (B) Left: box-plot presents the AML blast infiltration in the bone 459 
marrow. Right: box-plot shows the infiltration of the AML derived eosinophilic compartment in 460 
bone marrow. (C) The box-plot represents flow cytometric analysis showing the percentage 461 
of human CD11b membrane protein expression in the bone marrow of the AML xenografted 462 
mice with on the right side the flow cytometry plots of the individual mice. (D) Left: spleen 463 
lengths. Middle: histological analysis of the AML blast infiltration in the spleen. Right: AML 464 
derived eosinophilic compartment in the spleen. All box-plots represent the median and error 465 
bars define data distribution. Statistical analysis * p-value < 0.05. 466 
Research. 
on September 10, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 5, 2018; DOI: 10.1158/0008-5472.CAN-18-0250 
Research. 
on September 10, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 5, 2018; DOI: 10.1158/0008-5472.CAN-18-0250 
Research. 
on September 10, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 5, 2018; DOI: 10.1158/0008-5472.CAN-18-0250 
Research. 
on September 10, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 5, 2018; DOI: 10.1158/0008-5472.CAN-18-0250 
Research. 
on September 10, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 5, 2018; DOI: 10.1158/0008-5472.CAN-18-0250 
 Published OnlineFirst September 5, 2018.Cancer Res 
  
Kim R Kampen, Frank J.G. Scherpen, Hasan Mahmud, et al. 
  



































Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerres.aacrjournals.org/content/early/2018/09/05/0008-5472.CAN-18-0250
To request permission to re-use all or part of this article, use this link
Research. 
on September 10, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 5, 2018; DOI: 10.1158/0008-5472.CAN-18-0250 
